| pubmed-article:20852034 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20852034 | lifeskim:mentions | umls-concept:C0006864 | lld:lifeskim |
| pubmed-article:20852034 | lifeskim:mentions | umls-concept:C0279702 | lld:lifeskim |
| pubmed-article:20852034 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:20852034 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:20852034 | pubmed:dateCreated | 2010-11-24 | lld:pubmed |
| pubmed-article:20852034 | pubmed:abstractText | Several studies in cell cultures and in animal models have demonstrated that cannabinoids have important antitumoral properties. Because many of these effects are mediated through cannabinoid (CB) receptors CB? and CB?, the study of their expression in human neoplasms has become of great interest in recent years. Fresh and formalin-fixed tissue samples of 20 consecutive clear cell renal cell carcinomas (CCRCCs) were collected prospectively and analyzed for the expression of both CB receptors by using RT-PCR, Western blot (WB), and immunohistochemical techniques. RT-PCR assays demonstrated the expression of mRNA encoding the CB? in tumor tissue and in adjacent non-neoplastic kidney. Conversely, WB and IHC revealed a marked downregulation of CB? protein in tumor tissue; CB? was not expressed. The obtained data suggest a possible implication of the endocannabinoid system in renal carcinogenesis. A posttranscriptional downregulation of CB? and the absence of expression of CB? characterize CCRCC. | lld:pubmed |
| pubmed-article:20852034 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20852034 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20852034 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20852034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20852034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20852034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20852034 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20852034 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:20852034 | pubmed:issn | 1551-5044 | lld:pubmed |
| pubmed-article:20852034 | pubmed:author | pubmed-author:LarrinagaGork... | lld:pubmed |
| pubmed-article:20852034 | pubmed:author | pubmed-author:GilJavierJ | lld:pubmed |
| pubmed-article:20852034 | pubmed:author | pubmed-author:PintoFrancisc... | lld:pubmed |
| pubmed-article:20852034 | pubmed:author | pubmed-author:LópezJosé IJI | lld:pubmed |
| pubmed-article:20852034 | pubmed:author | pubmed-author:SanzBegoñaB | lld:pubmed |
| pubmed-article:20852034 | pubmed:author | pubmed-author:BlancoLorenaL | lld:pubmed |
| pubmed-article:20852034 | pubmed:author | pubmed-author:PérezItxaroI | lld:pubmed |
| pubmed-article:20852034 | pubmed:author | pubmed-author:CándenasMaría... | lld:pubmed |
| pubmed-article:20852034 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20852034 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:20852034 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20852034 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20852034 | pubmed:pagination | 1129-34 | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:meshHeading | pubmed-meshheading:20852034... | lld:pubmed |
| pubmed-article:20852034 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20852034 | pubmed:articleTitle | Cannabinoid CB? receptor is downregulated in clear cell renal cell carcinoma. | lld:pubmed |
| pubmed-article:20852034 | pubmed:affiliation | Department of Physiology, Faculty of Medicine and Dentistry, University of the Basque Country, Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), Leioa, Bizkaia, Spain. | lld:pubmed |
| pubmed-article:20852034 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20852034 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:1268 | entrezgene:pubmed | pubmed-article:20852034 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:20852034 | lld:entrezgene |
